Novo Holdings Makes Landmark Investment in Fungal Biotech Leader Sylvan to Accelerate Sustainable Solutions
Key Insights
Novo Holdings (search) has made its largest planetary health investment in Asia by directly investing in Sylvan (search), the world's leading fungal biotechnology company, while KKR (search) remains the majority shareholder.
The strategic investment will fund Sylvan (search)'s expansion through increased production capacity, upgraded R&D infrastructure, and deeper penetration into high-growth Asian markets.
Sylvan (search) aims to leverage Novo Holdings (search)' expertise to strengthen its global position in mushroom spawn markets and develop innovative bio-products including fungi-based materials, biopesticides, and nutritional supplements.
Novo Holdings (search), a prominent global life science investor, has signed definitive agreements to make a direct investment in Sylvan (search), the world's leading manufacturer of fungal biotechnology solutions. The transaction, announced on April 3, 2025, in Beijing, represents Novo Holdings' largest planetary health investment in Asia and its first in the fungal biotechnology sector. KKR (search), a leading global investment firm, will maintain its position as Sylvan's majority shareholder.
The strategic investment will provide Sylvan (search) with new capital to support its expansion plans, enabling increased production capacity, upgraded R&D infrastructure, and deeper penetration into high-growth markets, particularly in Asia. The company will also benefit from Novo Holdings (search)' extensive network and sector expertise to strengthen its position in the global mushroom spawn market and develop new high-impact bio-products.
Strategic Significance for Planetary Health
This investment marks a significant milestone in Novo Holdings (search)' global planetary health strategy and underscores its growing presence in Asia. The fungal biotechnology sector has been identified as a strategic priority due to its growth prospects and potential impact on planetary health.
"Sylvan (search) represents a significant milestone for our global Planetary Health strategy and underscores our growing presence in Asia," said Amit Kakar, Managing Partner and Head of Asia, and Deepa Hingorani, Partner, Head of Planetary Health Asia at Novo Holdings (search). "As a leader in fungal biotechnology, Sylvan is well-positioned to deliver sustainable innovations that support food security, reduce chemical use, and build a circular bioeconomy."
Founded in 1932 and headquartered in China, Sylvan (search) has established itself as the world's largest mushroom spawn and fungal biotechnology company. The company operates multiple production facilities globally and serves customers across 65 countries. Sylvan's mission is to harness the potential of fungal systems to create sustainable solutions addressing global challenges in food, health, agriculture, and materials.
Sustainable Advantages of Mushroom Cultivation
The modern mushroom sector offers significant sustainability benefits and circular economy value. Mushroom cultivation requires minimal land and water compared to traditional agriculture and utilizes agricultural waste as raw materials to produce high-quality proteins. This aligns perfectly with Novo Holdings (search)' investment focus on areas where science and technology can deliver returns while tackling global challenges.
China represents a particularly important growth market for Sylvan (search), where the downstream mushroom cultivation sector has experienced strong industrialization transition, driving greater demand for spawn and supporting agricultural modernization and rural economic growth across the country.
Leadership Perspectives on the Partnership
Jackie Qi, CEO of Sylvan (search), expressed enthusiasm about the new partnership: "Sylvan is delighted to welcome Novo Holdings (search) as our latest investor and to have the continued support of KKR (search), who have been a terrific strategic partner in our value creation journey. With this latest milestone, we are in an excellent position to pursue our ambition to become a global leader in fungal biotechnology solutions across four unique markets: Food, Health, Agriculture, and Materials."
Chris Sun, Partner and Head of China Private Equity at KKR (search), added: "We are pleased to welcome Novo Holdings (search) given their significant expertise in life sciences and planetary health. KKR is aligned with Novo Holdings in our commitment to drive the creation of sustainable global solutions. We are proud of the tremendous progress Sylvan (search) has achieved and believe this new strategic partnership will enable it to unlock even greater growth."
Expanding the Fungal Biotechnology Portfolio
With this investment, Sylvan (search) plans to develop new high-impact bio-products, including fungi-based materials, biopesticides, and nutritional supplements. These innovations have the potential to address critical global challenges in sustainable agriculture, food security, and environmental protection.
Novo Holdings (search)' Planetary Health Investments team, which spans three continents (Europe, North America, and Asia), focuses on investments in areas where science and technology can deliver returns while tackling global challenges, including feeding a growing world population, fighting climate change and drought, or creating sustainable cities.
As of year-end 2024, Novo Holdings (search) had total assets of €142 billion and is the controlling shareholder of Novo Nordisk A/S and Novonesis (search) A/S. Through its various investment teams, Novo Holdings invests in life science companies at all stages of development, making it an ideal partner for Sylvan (search)'s ambitious growth plans.
The collaboration between Novo Holdings (search), KKR (search), and Sylvan (search) represents a significant step forward in advancing sustainable biotechnology solutions that have the potential to transform multiple industries while contributing to planetary health and sustainability goals.